Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lebrikizumab in Moderate-to-Severe Atopic Dermatitis
NCT05990725Phase 3Completed
- Sponsor
- Almirall
- Start
- Nov 2023
- Primary completion
- Jun 2025
- Modality
- Monoclonal Antibodies
- Countries
- 3
01
Overview
A Phase 3 trial of lebrikizumab in atopic dermatitis (AD), sponsored by Almirall. Started Nov 2023; status: completed.
02
Drugs
lebrikizumab
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT05990725.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05990725.